-
Featured
Developing Tools for Active Surveillance Programs for Early-Stage Breast Cancer
An artificial intelligence tool developed by Manisha Bahl, MD, and colleagues identifies patients with low-risk early-stage breast cancer who are appropriate candidates for active surveillance programs, thus helping the patients avoid unnecessary surgery or radiation.
-
Cell-Free DNA Assay Can Identify Microsatellite Instability–High Status in Advanced Breast Cancer
Neelima Vidula, MD, Dejan Juric, MD, Aditya Bardia, MD, MPH and colleagues from multiple centers in the U.S. have demonstrated that plasma-based genotyping ("liquid biopsy") can identify microsatellite instability–high status in patients with metastatic breast cancer.
-
Editorial: Time for Change in Digital Breast Tomosynthesis Research
Daniel B. Kopans, MD, of the Radiology Department at Mass General, says it's time to stop researching digital breast tomosynthesis using sequential cohorts. He suggests a simple, direct method to study whether replacing synthetic two-dimensional images with full-field digital mammographic images is warranted.
-
ASCENT Trial: Sacituzumab Govitecan Has Survival Benefit in Metastatic Triple-negative Breast Cancer
Aditya Bardia, MD, MPH, is the first author of the report of the phase 3 ASCENT trial, which showed a significant survival benefit for sacituzumab govitecan compared with standard chemotherapy in patients with relapsed/refractory metastatic triple-negative breast cancer.
-
Editorial: Emerging Indications for Contrast-enhanced Mammography
Manisha Bahl, MD, MPH, a radiologist in the Breast Imaging Division in the Department of Radiology, explains the importance of a recent systematic review and meta-analysis that includes all literature published to date on contrast-enhanced mammography.
-
Novel Mechanism of Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer Identified by Mass General Researchers
Aditya Bardia, MD, MPH, Leif W. Ellisen, MD, PhD, and colleagues discovered that molecular alterations in both the antibody binding target and the payload target can potentially induce resistance to antibody–drug conjugates, a finding that has implications for the therapeutic sequencing of these agents.
Breast Cancer Contributors
-
Aditya Bardia, MD, MPH
Director of Precision Medicine, Center for Breast Cancer, Mass General Cancer Center, Founding Director, Molecular and Precision Medicine Metastatic Breast Cancer Clinic, Mass General Cancer Center, Assistant Professor in Medicine, Harvard Medical School
Recent Article
Cell-Free DNA Assay Can Identify Microsatellite Instability–High Status in Advanced Breast Cancer
-
Constance D. Lehman, MD, PhD
Director, Division of Breast Imaging, Massachusetts General Hospital, Professor of Radiology, Harvard Medical School
Recent Article
Pragmatic Approach to Managing and Interpreting Breast Imaging After COVID-19 Vaccination
-
Douglas Scott Micalizzi, MD, PhD
Clinical Assistant, Medicine, Massachusetts General Hospital, Instructor, Medicine, Harvard Medical School
Recent Article
New Insight into Breast Cancer Metastasis—and the Potential for Preventing It
-
Manisha Bahl, MD, MPH
Radiologist, Breast Imaging Division, Department of Radiology, Massachusetts General Hospital, Associate Professor of Radiology, Harvard Medical School
Recent Article
Editorial: Emerging Indications for Contrast-enhanced Mammography
-
Richard Ebright, PhD
Postgraduate Research Fellow, Massachusetts General Hospital Cancer Center
Recent Article
New Insight into Breast Cancer Metastasis—and the Potential for Preventing It
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
